We use cookies for a better user experience. Read our Privacy Policy

I Agree

Respiratory Virus Vaccines Market

Respiratory Virus Vaccines Market (Type: Inactivated/Killed Vaccines, Live-attenuated Vaccines, and Recombinant Vaccines; Route of Administration: Intramuscular, Intranasal, and Subcutaneous; Indication: Influenza, Measles, Mumps & Rubella, Coronavirus Disease [COVID-19], and Others; Age Group: Pediatric and Adults; and End User: Physician’s Office, Hospitals, Clinics, and Pharmacies/Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Phase 3 Trails of Sputnik V Vaccine Offer Hope for New COVID-19 Vaccine

Russia has been making strong claims by deeming Sputnik V as the first registered coronavirus (COVID-19) vaccine. However, the Union Health Ministry of India has denied Moscow’s claims about collaboration. As such, Russia is in talks to conduct phase 3 trials in different countries including India. The Gamaleya Research Institute and the Russia Defence Ministry are gaining recognition in the global respiratory virus vaccines market since President Putin announced the approval for Sputnik V coronavirus vaccine.

However, the Sputnik V vaccine is under scrutiny since phase 1 clinical trials of the Russian vaccine have not been published in the scientific literature. However, phase 2 trials of Russian vaccine involved several civilians and military volunteers. Thus, researchers and scientists in the Russia respiratory virus vaccines market are focusing on the final stage of testing for Sputnik V vaccine, which will involve the participation of a large number of volunteers.

Request a sample to get extensive insights into the Respiratory Virus Vaccines Market

Strategic Collaborations Instrumental in Coronavirus Vaccine Experiments

Apart from Russia, the Serum Institute of India is being highly publicized for developing billions of COVID-19 vaccine doses. Chief executive officer Adar Poonawalla is gaining popularity around the world as the vaccine vanguard, since its facilities have the capacity to produce billions of doses per year. Thus, companies in the respiratory virus vaccines market are taking cues from the largest producers of vaccine in the world to brew the raw materials necessary to experiment with coronavirus vaccines. As such, analysts at Transparency Market Research opine that the COVID-19 vaccine will be ready for deployment worldwide at the earliest by 2022.

Companies in the respiratory virus vaccines market are joining forces with leading biotechnology firms to progress in the pre-clinical test phase. Since the Coronavirus strain is similar to the previous SARS virus, it is potentially easier for scientists to advance in the pre-clinical test phases.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Research Funding Helps in Development of Long-lasting Influenza Vaccines

The National Institute of Allergy and Infectious Diseases (NIAID) has announced to provide a funding of ~US$ 51 Mn for the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, in an effort to develop long-lasting influenza vaccines. Thus, research centers in the respiratory virus vaccines market are increasing efforts to set up collaborative research teams that develop more durable and broadly protective influenza vaccines. Constructive efforts by scientists and research centers are bolstering the respiratory virus vaccines market, which is anticipated to advance at a steady CAGR of ~8% during the assessment period.

There is a growing need to effectively fight off influenza on the global level. Hence, pharmaceutical companies are increasing their R&D capabilities to innovate in improved formulations for respiratory virus vaccines.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Virus Vaccines Market

Immunization Programs Significantly Reduce Mortality Rates for Measles

The World Health Organization (WHO) claims that immunization has become an important tool for innovation in measles vaccines. With the help of immunization, several million infants are being vaccinated against measles, thus lowering mortality rates worldwide. Companies in the respiratory virus vaccines market are developing promising vaccines that protect the health of individuals from tuberculosis and influenza. They are intensifying their R&D capabilities to develop neutralizing antibodies and therapeutic respiratory virus vaccines that can generate value-grab opportunities for manufacturers.

There is a growing demand for needle-free vaccine administration to suit the needs of adolescents, pregnant women, and other age groups. Moreover, there is a need for robust vaccine storage and supply chains that hold promising potentials to transform immunization programs in the upcoming decade. Thus, timely access to reliable data is found to provide exciting opportunities for companies in the respiratory virus vaccines market.

Large Investments Play Key Role in Validated Efficacy of Mumps Vaccines

A research done by Emory Vaccine Center and the Centers for Disease Control and Prevention indicates that immunity against mumps virus appears to be insufficient among a fraction of college-aged individuals who were previously vaccinated in their childhood. Thus, companies in the respiratory virus vaccines market are increasing efforts to better understand the immune response to mumps and mumps vaccines. In the past decade, it has been observed that several mumps outbreaks have occurred among sports teams, college students, and close-knit communities in the U.S. Hence, pharmaceutical companies are focusing on developing effective mumps vaccines to lower the rate of mumps outbreaks.

Lack of strong immune response pertaining to mumps vaccine has emerged as a challenge for companies in the respiratory virus vaccines market. Manufacturers are directing large investment in clinical trials to demonstrate the safety and efficacy of mumps vaccines.

New TB Vaccines Hold Promising Potentials in Preventing Mtb in Individuals

Mycobacterium tuberculosis (Mtb) is responsible for high mortality rates, which is the highest among any single infectious pathogen worldwide. Hence, there is a demand for tuberculosis vaccines, since Bacille Calmette Guerin (BCG) is the only licensed vaccine, which is approaching its centenary. Moreover, the BCG vaccine if found to offer little to no protection against adult-type pulmonary tuberculosis. This has created a scope for companies in the respiratory virus vaccines market who can innovate in new TB vaccines.

Pharmaceutical companies are following the Preferred Product Characteristics (PPC) developed by the WHO to identify target populations who can be promising candidates for steering innovation in TB vaccines. These involve the participation of adults, adolescents, and infants. Companies are focusing on developing new TB vaccines for use in mass campaigns that are efficacious in preventing TB among adults and adolescents.

Analysts’ Viewpoint

France’s Pasteur Institute is increasing its R&D activities to use modified measles vaccine to trick the body into producing antibodies that are capable of fighting COVID-19 pathogens. Since seasonal influenza leads to hospitalization of tens of thousands of individuals in the U.S., companies in the respiratory virus vaccines market are tapping into growth opportunities in this domain. However, it is found that the circulating strain has drifted away from the strain that is in the mumps vaccine, which has led to mumps outbreaks among college institutes in the U.S. Hence, companies should invest in clinical trials to generate the desired immune response among individuals.

Respiratory Virus Vaccines Market: Overview

  • According to Transparency Market Research’s latest research report on the global respiratory virus vaccines market for the historical year (2018), base year (2019), and the forecast period (2020-2030), increase in incidence of respiratory infections is projected to drive the global respiratory virus vaccines market in the near future
  • According to the report, the global respiratory virus vaccines market was valued at US$ 6.4 Bn in 2019. It is anticipated to expand at a CAGR of ~8% from 2020 to 2030
  • In terms of type, the global respiratory virus vaccines market has been classified into inactivated/killed vaccines, live-attenuated vaccines, and recombinant vaccines. Based on route of administration, the global respiratory virus vaccines market has been categorized into intramuscular, intranasal, and subcutaneous. In terms of indication, the global respiratory virus vaccines market has been classified into influenza, measles, mumps & rubella, coronavirus disease (COVID-19), and others. In terms of age group, the global respiratory virus vaccines market has been divided into pediatric and adults. In terms of end user, the global respiratory virus vaccines market has been classified into physician offices, hospitals, clinics, pharmacies/stores, and others.

Increase in Burden of Respiratory Illnesses to Drive Respiratory Virus Vaccines Market

  • Rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections, and large number of pharmaceutical companies participating in the race to develop vaccine for the novel coronavirus are major factors projected to boost the respiratory virus vaccines market during the forecast period
  • As per the World Health Organization, 290,000 to 650,000 people die globally, every year, due to flu-related illnesses

Government Initiatives to Expand Vaccination Coverage to Propel Respiratory Virus Vaccines Market

  • In April 2017, the Government of Canada announced its decision to invest C$ 1.7 Mn in the Immunization Partnership Fund in order to fund three new projects aimed at expanding the vaccination coverage in Canada
  • In February 2017, the Government of India launched the ‘Pan-India campaign for Measles-Rubella Vaccination’ to help protect children from major childhood diseases viz. rubella and measles. This nationwide vaccination campaign aims to administer measles-rubella vaccine (MR-VAC) to children aged between nine months and 15 years of age.

Respiratory Virus Vaccines Market: Competition Landscape

  • This report profiles major players operating in the global respiratory virus vaccines market based on attributes such as company overview, financial overview, product portfolio, major brands, business strategies, and recent developments
  • The global respiratory virus vaccines market is marked by the presence of a few large players operating in the international market and some small players in regional markets. The top players hold a major share of the global respiratory virus vaccines market.
  • Developing a vaccine for the novel coronavirus has become a need of an hour. Amid the coronavirus crisis, several pharmaceutical companies are developing vaccine for COVID-19, with promising drug candidate in phase I and phase II in clinical trials.
  • Prominent players operating in the global respiratory virus vaccines market include -
    • CSL Limited
    • Sanofi
    • AstraZeneca
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Serum Institute of India Pvt. Ltd.
    • Bharat Biotech
    • Sinovac Biotech Ltd.
  • In April 2020, Sanofi entered into a collaboration with GlaxoSmithKline plc to accelerate the development of its vaccine against the novel coronavirus, SARS-CoV-2
  • In April 2020, AstraZeneca partnered with University of Oxford to develop a vaccine for COVID-19. The company has planned to submit the vaccine for fast track regulatory approval. It also plans to launch the vaccine in the U.K. and globally by the end for the year, if it gains regulatory approval.
  • In April 2020, Serum Institute of India Pvt. Ltd. entered into a partnership with University of Oxford to accelerate the development of a vaccine for COVID-19, developed by Oxford
  • The report on the global respiratory virus vaccines market discusses individual strategies, followed by company profiles of manufacturers of respiratory virus vaccines drugs and therapies. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global respiratory virus vaccines market.

Respiratory Virus Vaccines Market – Segmentation

Type

  • Inactivated/Killed Vaccines
  • Live-attenuated Vaccines
  • Recombinant Vaccines

Route of Administration

  • Intramuscular
  • Intranasal
  • Subcutaneous

Indication

  • Influenza
  • Measles, Mumps & Rubella
  • Coronavirus Disease (COVID-19)
  • Others

Age Group

  • Pediatric
  • Adults

End User

  • Physician’s Office
  • Hospitals
  • Clinics
  • Pharmacies/Stores

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of respiratory virus vaccines market?

Respiratory virus vaccines market to reach valuation of US$ 14.8 Bn by 2030

What is the anticipated CAGR of the respiratory virus vaccines market in the forecast period?

Respiratory virus vaccines market is anticipated to expand at a CAGR of ~8% from 2020 to 2030

What are the key driving factors for the growth of the respiratory virus vaccines market?

Respiratory virus vaccines market is driven by rise in prevalence of respiratory illnesses and demand for newer vaccines for the prevention of respiratory infections

Which is the rising prominent segment in the respiratory virus vaccines market?

The inactivated/killed vaccines segment accounted for a prominent share of the global respiratory virus vaccines market

Who are the key players in the global respiratory virus vaccines market?

Key players in the global respiratory virus vaccines market include CSL Limited, Sanofi, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc

1. Preface 

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Virus Vaccines Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Respiratory Virus Vaccines Market Analysis and Forecast, 2018–2030

5. Market Outlook

    5.1. Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) 

    5.2. Disease Prevalence & Incidence Rate globally with key countries 

    5.3. Pipeline Analysis

    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact) Pricing Analysis 

6. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type

    6.1. Introduction & Definition 

    6.2. Global Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        6.2.1. Inactivated/Killed Vaccines

        6.2.2. Live-attenuated Vaccines

        6.2.3. Recombinant vaccines

    6.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type

7. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration

    7.1. Introduction & Definition 

    7.2. Global Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

        7.2.1. Intramuscular

        7.2.2. Intranasal

        7.2.3. Subcutaneous

    7.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration

8. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication 

    8.1. Global Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        8.1.1. Influenza

        8.1.2. Measles, Mumps & Rubella

        8.1.3. Coronavirus Disease (COVID-19)

        8.1.4. Others

    8.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication

9. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group

    9.1. Global Respiratory Virus Vaccines Market Value Forecast, by Age Group, 2018–2030

        9.1.1. Pediatric 

        9.1.2. Adults

    9.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group

10. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user

    10.1. Global Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        10.1.1. Physician’s Office

        10.1.2. Hospitals

        10.1.3. Clinics

        10.1.4. Pharmacy/Store

        10.1.5. Others

    10.2. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user

11. Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region

    11.1. Introduction 

    11.2. Global Respiratory Virus Vaccines Market Value Forecast, by Region, 2018–2030

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region

12. North America Respiratory Virus Vaccines Market Analysis and Forecast 

    12.1. Introduction

    12.2. North America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        12.2.1. Inactivated/Killed Vaccines

        12.2.2. Live-attenuated Vaccines

        12.2.3. Recombinant vaccines

    12.3. North America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

        12.3.1. Intramuscular

        12.3.2. Intranasal

        12.3.3. Subcutaneous

    12.4. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        12.4.1. Influenza

        12.4.2. Measles, Mumps & Rubella

        12.4.3. Coronavirus Disease (COVID-19)

        12.4.4. Others

    12.5. North America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        12.5.1. Pediatric 

        12.5.2. Adults

    12.6. North America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        12.6.1. Physician Offices

        12.6.2. Hospitals

        12.6.3. Clinics

        12.6.4. Pharmacy/Store

        12.6.5. Others

    12.7. North America Respiratory Virus Vaccines Market Value Forecast, by Country, 2018–2030

        12.7.1. U.S.

        12.7.2. Canada

    12.8. North America Respiratory Virus Vaccines Market Attractiveness Analysis

        12.8.1. By Type

        12.8.2. By Route of Administration

        12.8.3. By Indication

        12.8.4. By Age Group

        12.8.5. By End-user

        12.8.6. By Country

13. Europe Respiratory Virus Vaccines Market Analysis and Forecast 

    13.1. Introduction

    13.2. Europe Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        13.2.1. Inactivated/Killed Vaccines

        13.2.2. Live-attenuated Vaccines

        13.2.3. Recombinant vaccines

    13.3. Europe Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

        13.3.1. Intramuscular

        13.3.2. Intranasal

        13.3.3. Subcutaneous

    13.4. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        13.4.1. Influenza

        13.4.2. Measles, Mumps & Rubella

        13.4.3. Coronavirus Disease (COVID-19)

        13.4.4. Others

    13.5. Europe Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        13.5.1. Pediatric 

        13.5.2. Adults

    13.6. Europe Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        13.6.1. Physician Offices

        13.6.2. Hospitals

        13.6.3. Clinics

        13.6.4. Pharmacy/Store

        13.6.5. Others

    13.7. Europe Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Spain

        13.7.5. Italy 

        13.7.6. Rest of Europe

    13.8. Europe Respiratory Virus Vaccines Market Attractiveness Analysis

        13.8.1. By Type

        13.8.2. By Route of Administration

        13.8.3. By Indication

        13.8.4. By Age Group

        13.8.5. By End-user

        13.8.6. By Country/Sub-region

14. Asia Pacific Respiratory Virus Vaccines Market Analysis and Forecast 

    14.1. Introduction

    14.2. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        14.2.1. Inactivated/Killed Vaccines

        14.2.2. Live-attenuated Vaccines

        14.2.3. Recombinant vaccines

    14.3. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

        14.3.1. Intramuscular

        14.3.2. Intranasal

        14.3.3. Subcutaneous

    14.4. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        14.4.1. Influenza

        14.4.2. Measles, Mumps & Rubella

        14.4.3. Coronavirus Disease (COVID-19)

        14.4.4. Others

    14.5. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        14.5.1. Pediatric 

        14.5.2. Adults

    14.6. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        14.6.1. Physician Offices

        14.6.2. Hospitals

        14.6.3. Clinics

        14.6.4. Pharmacy/Store

        14.6.5. Others

    14.7. Asia Pacific Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

        14.7.1. Japan

        14.7.2. China

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis

        14.8.1. By Type

        14.8.2. By Route of Administration

        14.8.3. By Indication

        14.8.4. By Age Group

        14.8.5. By End-user

        14.8.6. By Country/Sub-region

15. Latin America Respiratory Virus Vaccines Market Analysis and Forecast 

    15.1. Introduction

    15.2. Latin America Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        15.2.1. Inactivated/Killed Vaccines

        15.2.2. Live-attenuated Vaccines

        15.2.3. Recombinant vaccines

    15.3. Latin America Respiratory Virus Vaccines Market Value Forecast, by Route of Administration, 2018–2030

        15.3.1. Intramuscular

        15.3.2. Intranasal

        15.3.3. Subcutaneous

    15.4. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        15.4.1. Influenza

        15.4.2. Measles, Mumps & Rubella

        15.4.3. Coronavirus Disease (COVID-19)

        15.4.4. Others

    15.5. Latin America Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        15.5.1. Pediatric 

        15.5.2. Adults

    15.6. Latin America Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        15.6.1. Physician Offices

        15.6.2. Hospitals

        15.6.3. Clinics

        15.6.4. Pharmacy/Store

        15.6.5. Others

    15.7. Latin America Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Latin America Respiratory Virus Vaccines Market Attractiveness Analysis

        15.8.1. By Type

        15.8.2. By Route of Administration

        15.8.3. By Indication

        15.8.4. By Age Group

        15.8.5. By End-user

        15.8.6. By Country/Sub-region

16. Middle East & Africa Respiratory Virus Vaccines Market Analysis and Forecast 

    16.1. Introduction

    16.2. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Type, 2018–2030

        16.2.1. Inactivated/Killed Vaccines

        16.2.2. Live-attenuated Vaccines

        16.2.3. Recombinant vaccines

    16.3. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Route of Administration , 2018–2030

        16.3.1. Intramuscular

        16.3.2. Intranasal

        16.3.3. Subcutaneous

    16.4. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        16.4.1. Influenza

        16.4.2. Measles, Mumps & Rubella

        16.4.3. Coronavirus Disease (COVID-19)

        16.4.4. Others

    16.5. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Indication, 2018–2030

        16.5.1. Pediatric 

        16.5.2. Adults

    16.6. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by End-user, 2018–2030

        16.6.1. Physician Offices

        16.6.2. Hospitals

        16.6.3. Clinics

        16.6.4. Pharmacy/Store

        16.6.5. Others

    16.7. Middle East & Africa Respiratory Virus Vaccines Market Value Forecast, by Country/Sub-region, 2018–2030

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis

        16.8.1. By Type

        16.8.2. By Route of Administration

        16.8.3. By Indication

        16.8.4. By Age Group

        16.8.5. By End-user

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player - Competition Matrix (by tier and size of companies)

    17.2. Global Respiratory Virus Vaccines Market Position Analysis, by Company, 2019

    17.3.  Company Profiles

        17.3.1. CSL Limited

            17.3.1.1. Company Description

            17.3.1.2. Business Overview

            17.3.1.3. Financial Overview

            17.3.1.4. Strategic Overview

            17.3.1.5. SWOT Analysis

        17.3.2. Sanofi

            17.3.2.1. Company Description

            17.3.2.2. Business Overview

            17.3.2.3. Financial Overview

            17.3.2.4. Strategic Overview

            17.3.2.5. SWOT Analysis

        17.3.3. AstraZeneca

            17.3.3.1. Company Description

            17.3.3.2. Business Overview

            17.3.3.3. Financial Overview

            17.3.3.4. Strategic Overview

            17.3.3.5. SWOT Analysis

        17.3.4. Merck & Co., Inc.

            17.3.4.1. Company Description

            17.3.4.2. Business Overview

            17.3.4.3. Strategic Overview

            17.3.4.4. Financial Overview

            17.3.4.5. SWOT Analysis

        17.3.5. GlaxoSmithKline plc

            17.3.5.1. Company Description

            17.3.5.2. Business Overview

            17.3.5.3. Strategic Overview

            17.3.5.4. Financial Overview

            17.3.5.5. SWOT Analysis

        17.3.6. Serum Institute of India Pvt. Ltd.

            17.3.6.1. Company Description

            17.3.6.2. Business Overview

            17.3.6.3. Financial Overview

            17.3.6.4. Strategic Overview

            17.3.6.5. SWOT Analysis

        17.3.7. Bharat Biotech

            17.3.7.1. Company Description

            17.3.7.2. Business Overview

            17.3.7.3. Financial Overview

            17.3.7.4. Strategic Overview

            17.3.7.5. SWOT Analysis

        17.3.8. Sinovac Biotech Ltd.

            17.3.8.1. Company Description

            17.3.8.2. Business Overview

            17.3.8.3. Financial Overview

            17.3.8.4. Strategic Overview

            17.3.8.5. SWOT Analysis

List of Tables:

Table 01 Pipeline Analysis (1/4)

Table 02 Pipeline Analysis (2/4)

Table 03 Pipeline Analysis (3/4)

Table 04 Pipeline Analysis (4/4)

Table 05 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (1/3)

Table 06 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (2/3)

Table 07 Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (3/3)

Table 08 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 12 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 13 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 14 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 15 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 16 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 17 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 18 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 19 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 20 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 21 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 22 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 23 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 24 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 25 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 26 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 27 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 28 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 29 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 30 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 31 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 32 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 33 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 34 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 35 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 36 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 37 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 38 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 39 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 40 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 41 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 42 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by Age Group, 2018–2030

Table 43 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, by End-user, 2018–2030

List of Figures:

Figure 01 Global Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 02 Global Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 03 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 04 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Inactivated/Killed Vaccines, 2018-2030 

Figure 05 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Live-attenuated Vaccines, 2018-2030 

Figure 06 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant vaccines, 2018-2030 

Figure 07 Global Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 08 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 09 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intramuscular, 2018-2030 

Figure 10 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Intranasal, 2018-2030 

Figure 11 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2018-2030 

Figure 12 Global Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 13 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 14 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Influenza, 2018-2030 

Figure 15 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Measles, Mumps & Rubella, 2018-2030 

Figure 16 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Coronavirus Disease (COVID-19), 2018-2030 

Figure 17 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030 

Figure 18 Global Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 19 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 20 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pediatric, 2018-2030 

Figure 21 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Adult, 2018-2030 

Figure 22 Global Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 23 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Figure 24 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Physician Offices, 2018-2030 

Figure 25 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2018-2030 

Figure 26 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2018-2030 

Figure 27 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharmacy/Store, 2018-2030 

Figure 28 Global Respiratory Virus Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2018-2030 

Figure 29 Global Respiratory Virus Vaccines Market Value Share Analysis, by Region, 2019 and 2030

Figure 30 Global Respiratory Virus Vaccines Market Attractiveness Analysis, by Region, 2020-2030

Figure 31 North America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 32 North America Respiratory Virus Vaccines Market Value Share Analysis, by Country, 2019 and 2030

Figure 33 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030

Figure 34 North America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 35 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 36 North America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 37 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 38 North America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 39 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 40 North America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 41 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 42 North America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 43 North America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Figure 44 Europe Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 45 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 46 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Country, 2020-2030

Figure 47 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 48 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 49 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 50 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 51 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 52 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 53 Europe Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 54 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 55 Europe Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 56 Europe Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Figure 57 Asia Pacific Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 58 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 59 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 60 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 61 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 62 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 63 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 64 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 65 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 66 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 67 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 68 Asia Pacific Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 69 Asia Pacific Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Figure 70 Latin America Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 71 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 72 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 73 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 74 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 75 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 76 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 77 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 78 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 79 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 80 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 81 Latin America Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 82 Latin America Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Figure 83 Middle East & Africa Respiratory Virus Vaccines Market Value (US$ Mn) Forecast, 2018-2030

Figure 84 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 85 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2020-2030

Figure 86 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Type, 2019 and 2030

Figure 87 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Type, 2020-2030

Figure 88 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 89 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Route of Administration, 2020-2030

Figure 90 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Indication, 2019 and 2030

Figure 91 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Indication, 2020-2030

Figure 92 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by Age Group, 2019 and 2030

Figure 93 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by Age Group, 2020-2030

Figure 94 Middle East & Africa Respiratory Virus Vaccines Market Value Share Analysis, by End-user, 2019 and 2030

Figure 95 Middle East & Africa Respiratory Virus Vaccines Market Attractiveness Analysis, by End-user, 2020-2030

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

626

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved